Imbruvica (Ibrutinib) Patent Expiration, LOE Window & CMS Spending
Imbruvica (Ibrutinib) by AbbVie: FDA Orange Book core substance LOE 2034-04-30 (last listed 2035-04-24), 1 AB generics, $2.36B 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AbbVie |
| FDA Application & Pathway | N205552 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2034-04-30 |
| Last Listed Patent or Exclusivity Date | 2035-04-24 |
| Orange Book Patents (*PED Extensions) | 67 patents (33 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $2.36B |
| 2024 Medicare Part D Spend | $2.27B |
| 2024 Medicaid Spend | $89.6M |
| Reported Wholesale Price Change (CA SB 17) | 12 WAC filings (max 22.5% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.